FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, more specifically to therapeutic proteins based on chimeric domains of interleukin-1 (hereinafter – IL-1) family proteins; it can be used in medicine for the treatment of autoimmune disease, inflammatory disease or cancer, as well as for the treatment of an individual suffering from dry eye or allergic conjunctivitis or having a risk of developing the specified pathology. A chimeric protein is constructed based on IL-1beta and IL-1Ra domains.
EFFECT: invention allows for producing protein, which binds to IL-1 receptor I (IL-1RI) and inhibits its activity.
45 cl, 12 dwg, 10 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES DIRECTED AGAINST THE INTERLEUKIN 36 (IL-36R) RECEPTOR | 2016 |
|
RU2745898C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| COMBINATION DRUG CONTAINING CORTICOSTEROID AND EXOSOMES | 2010 |
|
RU2557897C2 |
| COMBINATION PREPARATIONS WITH CYTOKINE ANTAGONIST AND CORTICOSTEROID | 2010 |
|
RU2526161C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| ACTIVATED POLYPEPTIDES OF INTERLEUKIN 12 AND METHODS OF USE THEREOF | 2019 |
|
RU2826183C2 |
| ACTIVATED POLYPEPTIDES OF INTERLEUKIN-2 AND METHODS OF USE THEREOF | 2019 |
|
RU2826454C2 |
| METHODS OF TREATING PATHOLOGICAL CONDITIONS WITH ANTIBODIES WHICH BIND TO THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2013 |
|
RU2718751C2 |
| THERAPEUTIC PRODUCT CONTAINING IL-33 ANTAGONIST FOR THE TREATMENT OF ENDOMETRIOSIS | 2018 |
|
RU2791705C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
